Low-dose TMP-SMX for Pneumocystis pneumonia (PCP)
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This Phase 3 study tests whether low-dose trimethoprim-sulfamethoxazole (also called TMP-SMX) can treat Pneumocystis pneumonia (PCP) in people with weakened immune systems. It may help improve treatment while reducing side effects compared with standard dosing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years old or older.
- You have a weakened immune system (for example: HIV, organ transplant, blood cancers, chemotherapy, long-term steroids, or other immune-suppressing medicines).
- You are currently in the hospital, emergency department, or a day hospital for this illness.
- Your doctors have diagnosed PCP as “proven” or “probable” using specific criteria.
- You have NOT had a severe allergic reaction to TMP-SMX or other sulfa medicines.
- You haven’t already taken TMP-SMX to prevent PCP for 4 or more weeks, and you haven’t had more than 96 hours of any PCP treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different lengths of steroid treatment for people with severe Pneumocystis pneumonia (a serious lung infection). If you have improved enough by day 10 to breathe without oxygen, the study will see if stopping steroids sooner is as safe and effective as continuing them.
This study compares different second-line antibiotics for treating Pneumocystis pneumonia (a serious lung infection) in people with weakened immune systems. It aims to find the best alternative when the standard treatment cannot be used.
This study tests whether short-term steroid treatment helps adults with a specific lung infection (PCP) that happens with HIV/AIDS. It compares outcomes in people who start steroids soon after admission while also taking standard PCP antibiotics.
This Phase 2 trial tests rezafungin, an antifungal medicine, to treat Pneumocystis pneumonia (PCP) in adults living with HIV. It may help people recover faster or more effectively from this serious lung infection.
This trial tests a new way to diagnose pneumocystis, a lung infection that can affect people with weakened immune systems. It may help find the infection faster and more accurately using samples taken from your lungs.
This trial tests caspofungin, a medicine, for treating Pneumocystis pneumonia (PCP) in people living with HIV. It aims to see if it works better than standard treatments.
Hear when a new Pneumocystis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.